Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.14473 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Yun Jeong Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurology, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT), Ministry of Health and Welfare.
Abstract (Originalsprache)
INTRODUCTION Alzheimer's disease (AD) is now diagnosed biologically. Since subjective cognitive decline (SCD) may indicate preclinical AD, assessing AD‐biomarkers is crucial. We investigated cognitive and neurodegenerative trajectories in SCD over 24 months based on biomarker positivity, and evaluated the predictive value of plasma biomarkers. METHODS The CoSCo prospective cohort included older adults with SCD. Participants were categorized into high‐ and low‐risk groups based on plasma biomarkers (amyloid beta [Aβ] 42/40, phosphorylated tau 181 [p‐tau181], and glial fibrillary acidic protein [GFAP]), and magnetic resonance imaging (MRI) findings to compare outcomes. RESULTS High‐risk SCDs ( n = 23, 23%) revealed greater decline in general cognition, memory recall, frontal function, and hippocampal volumes compared to low‐risk SCDs. Combined scores of plasma and MRIs yielded the best predictions compared with other biomarker categories. DISCUSSION SCD participants with high‐risk experience faster cognitive and neurodegenerative declines. A combination of plasma biomarkers and MRIs could be used for screening and prognosis. Highlights This is part of a multicenter prospective cohort study in Korea. We investigated cognitive and atrophic trajectories in SCD over 24 months. High risk SCDs revealed greater cognitive decline and hippocampal atrophy. Integration of plasma and MRIs yielded better predictions than other categories. Risk stratification using plasma and MRIs can be used for screening and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Neurology, Inha University College of Medicine, Incheon, Republic of Korea.
- Neurology, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
- Neurology, College of Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
- Neurology, ROA clinic, Seongnam, Republic of Korea.
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
- Ministry of Health and Welfare
Zitieren
APA
Hong, Y. J., Choi, S. H., Kim, S., Jeong, J. H., Park, K. H., Wang, M. J., Kang, S., Yang, D. W., & CoSCo study group (2025). Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14473
Vancouver
Hong YJ, Choi SH, Kim S, Jeong JH, Park KH, Wang MJ, et al. Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14473
BibTeX
@article{Hong2025,
author = {Hong, Yun Jeong and Choi, Seong Hye and Kim, SangYun and Jeong, Jee Hyang and Park, Kee Hyung and Wang, Min Jeong and Kang, Sungmin and Yang, Dong Won and CoSCo study group, CoSCo study group},
title = {Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.14473}
}
EUVIMED